Psychopharmacology
October 19, 2026
Landon M. Klein, Jared M. Kopelman, Richard F Sharp et al.
Classical psychedelic drugs such as the tryptamine psilocybin can alter temporal perception. Previously, the phenylethylamine psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI), a 5-HT2A receptor agonist, altered timing precision and accuracy in mice performing the discrete-trials temporal discrimination task (TDT), a retrospective timing task where subjects differentially respond depending on...
Neuropsychopharmacology
July 21, 2026
Alannah Miranda, Breanna M Holloway, Elizabeth Peek et al.
Cannabis use is highly prevalent among people with bipolar disorder, potentially due to a desire to self-medicate against symptoms, such as racing thoughts and poor concentration. Such symptoms are associated with attention and inhibitory control deficits, functions that are regulated in-part by temporal perception. Temporal perception is impaired in BD and is slowed by acute cannabis exposure....
Journal of Cannabis Research
January 2, 2026
Sunitha Vemuri, Samantha M. Ayoub, Arpi Minassian et al.
Cannabinoids have proven to useful for attenuating adverse effects of HIV. People living with HIV use cannabis at higher rates, with evidence suggesting it alleviates physiological symptoms such as nausea, loss of appetite, etc.. Cannabis can alter physiology as well as essential behavioral functions such as motivation. This study investigated the effect of delta-9-tetrahydrocannabinol (THC),...
Neuropharmacology
May 1, 2025
Michael Noback, Johnny A Kenton, Adam K. Klein et al.
2 citations
Treating amotivated states remains difficult. Classical psychedelic drugs (5-HT2A receptor agonists) such as LSD and psilocybin have shown therapeutic potential in treating such symptoms, but their development has been hindered by their undesirable hallucinogenic effects. There is increasing evidence that administration of psychedelics at dose levels too low to evoke a hallucinogenic effect...
Brain, Behavior, and Immunity
April 1, 2025
Samantha M. Ayoub, Sunitha Vemuri, Elizabeth B. Hoang et al.
HIV-associated neurocognitive impairment (NCI) is an untreated concern among people living with HIV (PLWH). Cannabis use in PLWH may complicate outcomes on cognition, with evidence to suggest function-dependent effects that are modulated by several factors including use patterns (e.g., frequency of use) and demographic influences (e.g., age). Animal studies can control for these factors. Here,...
Behavioral Sleep Medicine
March 3, 2024
Alannah Miranda, Elizabeth Peek, Sonia Ancoli-Israel et al.
Both sleep and cognition are partially modulated by the endocannabinoid (ECB) system. Cannabis has been reported to have effects on sleep and cognition. This review aims to summarize the recent literature on the ECB system, the role of cannabis and the ECB system on sleep regulation and cognition. Further, this review will identify existing gaps in knowledge and suggest potential targets for...
Neuropsychopharmacology
August 2023
Michael M. Tranter, Samarth Aggarwal, Jared W Young et al.
The ability to appropriately update the value of a given action is a critical component of flexible decision making. Several psychiatric disorders, including schizophrenia, are associated with impairments in flexible decision making that can be evaluated using the probabilistic reversal learning (PRL) task. The PRL task has been reverse-translated for use in rodents. Disrupting glutamate...
The International Journal of Neuropsychopharmacology
November 12, 2021
Benjamin Z Roberts, Arpi Minassian, Adam L. Halberstadt et al.
HIV-associated neurocognitive disorder (HAND) is commonly observed in persons living with HIV (PWH) and is characterized by cognitive deficits implicating disruptions of fronto-striatal neurocircuitry. Such circuitry is also susceptible to alteration by cannabis and other drugs of abuse. PWH use cannabis at much higher rates than the general population, thus prioritizing the characterization of...
medRxiv
April 29, 2020
T. Jordan Walter, Nina Pocuca, Jared W Young et al.
1 citation
preprint
ABSTRACT Bipolar disorder (BD) and cannabis use are highly comorbid and are each associated with cognitive impairment. It is therefore important to understand the relationship between cannabis use and cognition in people with BD, as cannabis use in BD may be associated with greater cognitive impairment. We performed a scoping review to determine how much and what is currently known in this...
Behavioural Brain Research
May 17, 2019
Nurith Amitai, Susan B Powell, Jared W Young
Schizophrenia is a debilitating neurodevelopmental disorder affecting 1% of the global population with heterogeneous symptoms including positive, negative, and cognitive. While treatment for positive symptoms exists, none have been developed to treat negative symptoms. Animal models of schizophrenia are required to test targeted treatments and since patients exhibit reduced effort (breakpoints)...
Psychopharmacology
February 22, 2018
S. Barnes, Jared W Young, A. Markou et al.
Attentional processing deficits are a core feature of schizophrenia, likely contributing to the persistent functional and occupational disability observed in patients with schizophrenia. The pathophysiology of schizophrenia is hypothesized to involve dysregulation of NMDA receptor-mediated glutamate transmission, contributing to disruptions in normal dopamine transmission. Preclinical...
Psychopharmacology
October 2016
Zackary A Cope, Adam L. Halberstadt, Jordy Van Enkhuizen et al.
The five-choice serial reaction time task (5-CSRTT) is regularly used to study attention and impulsivity. In the 5-CSRTT, rodents initiate a trial, then after an inter-trial interval (ITI), a light appears in one of five holes. Responding in the lit vs. unlit hole reflects attention (accuracy), while responding prematurely before a light appears is suggested to reflect impulsivity/response...
Neuropharmacology
March 2012
Sam A Barnes, Jared W Young, Jo C Neill
It is well documented that schizophrenia patients exhibit dysfunction in various cognitive domains, including attention/vigilance, as demonstrated by impaired performance in the myriad of Continuous Performance Tests (CPTs). NMDA receptor antagonists provide a pharmacological model in animals of the cognitive disruption presented in the disorder. We therefore examined the effects of a...